Latest United States Startup Funding Rounds
Startup funding in United States: recent rounds, the companies behind them and their participating investors.
- Rounds
- 2,137 Jan 1 – Oct 9, 2026
- Disclosed funding
- $200.7B 1769 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| RA Rep AICompany profile AI platform for ecommerce brands covering shopper intent, conversion, and post-purchase support AI platform for ecommerce brands covering shopper intent, conversion, and post-purchase support | $6.2M | StrategicUndisclosed | Ecommerce | United States | Investors | |
| S SarisCompany profile Agentic workflow platform for banks and credit unions automating lending, compliance, and back-office operations Agentic workflow platform for banks and credit unions automating lending, compliance, and back-office operations | $28.8M | Series A | Fintech | United States | Investors | |
| C Provides full-stack insurance platform for commercial insurance infrastructure | $106M | Series B1Series B | Fintech | United States | Investors | |
| T TriomicsCompany profile Building AI infrastructure to turn complex cancer records into structured intelligence Building AI infrastructure to turn complex cancer records into structured intelligence | $22M | Series B | Healthtech | United States | Investors | |
| R ReactorCompany profile Developer platform providing infrastructure for real-time generative video and interactive world models Developer platform providing infrastructure for real-time generative video and interactive world models | $59M | Undisclosed | AI | United States | Investors | |
| S AI-native marketing agency accelerating pharma commercialization | $21M | Series A | Healthtech | United States | Investors | |
| P PsileraCompany profile Develops next-generation neuroplastogens and psychedelic therapies for neurological conditions Develops next-generation neuroplastogens and psychedelic therapies for neurological conditions | $8.8M | Seed+Seed | Biotech | United States | Investors Undisclosed | |
| EL Ember LifeSciencesCompany profile Reusable temperature-controlled shipping platform for pharmaceutical cold chain distribution Reusable temperature-controlled shipping platform for pharmaceutical cold chain distribution | $27M | Series A | Healthtech | United States | Investors | |
| ST Secretome TherapeuticsCompany profile Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy | $30M | Series A | Biotech | United States | Investors | |
| PB Protuoso BiosciencesCompany profile Develops AI-enabled multifunctional biologics platform targeting cardiometabolic, oncology, and autoimmune diseases Develops AI-enabled multifunctional biologics platform targeting cardiometabolic, oncology, and autoimmune diseases | $9.5M | Seed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
Nous Research, Santé, Vitalize
126rounds3led - 2Andreessen Horowitz (a16z)
TypeSafe AI, Arena, Vesta
94rounds18led - 3General Catalyst
Minerva Humanoids, Melius
65rounds6led - 4Alumni Ventures
Savvy Wealth, Ocular AI, Mona
56rounds0led - 5Khosla Ventures
Arena, Vinci, Conway Research
54rounds5led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.